Chemodenervation of the Larynx
Botulinum neurotoxin (BoNT) has existed for thousands of years; however, it was not medically utilized until investigations into its therapeutic use began in sincerity during the late 1970s and 1980s. This, coupled with the reclassification of spasmodic dysphonia as a focal dystonia, led to the use...
Main Authors: | Rachel Kaye, Andrew Blitzer |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2017-11-01
|
Series: | Toxins |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6651/9/11/356 |
Similar Items
-
Retrospective review of dosing trends in botulinum toxin injections for the treatment of adductor spasmodic dysphonia in a long-term cohort
by: Gabrielle French, et al.
Published: (2020-01-01) -
Botulinum Neurotoxin Therapy in the Clinical Management of Laryngeal Dystonia
by: Winnie Yeung, et al.
Published: (2022-12-01) -
Life Threatening Delayed Complication of Botulinum Toxin Injection for Treatment of Spasmodic Dysphonia
by: Danylo Yershov, et al.
Published: (2020-06-01) -
Optimizing Botox regimens in patients with adductor spasmodic dysphonia and essential tremor of voice: A 31‐year experience
by: Amy Stone, et al.
Published: (2022-10-01) -
O uso da toxina botulínica no tratamento da distonia laríngea (disfonia espasmódica): estudo preliminar com doze pacientes Use of botulinum toxin in the treatment of laryngeal dystonia (spasmodic dysphonia): preliminary study of twelve patients
by: Hélio A. G. Teive, et al.
Published: (2001-03-01)